The winter solstice, the shortest day (and longest night) of the year, is less than a month away. And with cold, darkened days comes the phenomenon of Seasonal Affective Disorder (SAD), a form of depression that usually affects people in the late fall and early winter. To treat this kind of seasonal depression, thought to be linked with a relative lack of light, some patients with SAD take to “light therapy” wherein they’re exposed to bright, artificial light from a screen—and new research suggests it may also be effective in treating another kind of depression, the type that’s associated with bipolar disorder.

People suffering from bipolar disorder (as nearly 6 million U.S. adults do) typically have periods of manic behavior followed by depressive bouts when they feel sad, lonely, helpless, or fatigued. These manic and depressive states can last days, weeks, or months and make even everyday activities difficult to perform.

One of the theories supporting light therapy to treat seasonal depression is that the condition is linked in some way with a lack of sunlight which causes low levels of serotonin production in the skin. To counteract this effect, patients sit in front of a bright, white light emitted from a screen (taking Vitamin D or prescribed antidepressants can also help the process, according to the National Institute of Mental Health).

In the (very early) study of light therapy’s effect on people with depression related to bipolar disorder, Northwestern University researchers had 46 patients with moderate bipolar depression undergo either light therapy or a placebo process with a red LED light. The results, while preliminary, were striking: 68% of patients treated with white light therapy reported a remission in depression symptoms compared with just 22% of the patients exposed to LED light. The participants sat about a foot away from the light box (without necessarily looking right at it) for 15 minutes per day before gradually working up to hour-long sessions.

The “dosing” process was a bit different from the bright light treatment used in Seasonal Affective Disorder, though—patients received their light therapy in the afternoon rather than the morning, for instance, because of the procedure’s potential to induce a manic state in people with bipolar disorder. And lead study author Dorothy Sit says there’s still much more research needed into the therapy’s promise in this particular kind of depression. For now, though, the study is helping shed light on a non-medication approach to combating mental illness.

Read on for the day’s news.

DIGITAL HEALTH

Rumors swirl around potential Apple entry into electronic health records market. Patent filings by Apple have tongues wagging about the company's possible entry into the electronic health records (EHR) market. The tech giant has reportedly secured several patents in the space—and the newest push may also involve health data that includes users' biometric data, such as heart function or blood pressure. (Healthcare IT News)

INDICATIONS

Top execs out at Teva in massive restructure. Beleaguered generic drug giant Teva Pharmaceutical Industries was already reportedly gearing up for thousands of job cuts across the globe, including a 20-25% reduction in its Israeli workforce and double-digit percent cuts in the U.S., too. Some big names are now also part of the culling, the company announced Monday. New CEO Kare Schultz announced a leadership restructure that includes that departure of Dr. Michael Hayden (Teva's R&D chief), Dr. Rob Koremans (president and CEO of the global specialty medicines arm), and Dipankar Bhattacharjee (president and CEO of the global generic medicines arm) by the end of the year. (Fortune)

THE BIG PICTURE

States brace for Children's Health Insurance Program funding to run dry. Congress has yet to reauthorize the Children's Health Insurance Program, which provides health coverage to nearly nine million American kids in low- and middle-income families, since its expiration in September. Now five states are bracing for funding to dry out completely before the end of the year. A House bill to extend CHIP for five years passed that chamber but the Senate is still working out the details over its own legislation, with lawmakers butting heads at financial offsets to fund the program. (The Hill)

REQUIRED READING

Meredith Is Buying Time Inc. for $1.8 Billion, by Reuters

A Guide to the Supreme Court's Blockbuster Patent Case, by Jeff John Roberts

All of Your Cyber Monday Questions Answered, by Sarah Gray

Tesla's Big Promises Depend on Advancing Battery Technology, by David Z. Morris